Shrestha R, Mohankumar K, Martin G, Hailemariam A, Lee S, Jin U
J Exp Clin Cancer Res. 2021; 40(1):392.
PMID: 34906197
PMC: 8670039.
DOI: 10.1186/s13046-021-02199-9.
Lacey A, Hedrick E, Cheng Y, Mohankumar K, Warren M, Safe S
Mol Cancer Ther. 2018; 17(12):2756-2766.
PMID: 30190424
PMC: 6279487.
DOI: 10.1158/1535-7163.MCT-18-0118.
Mohamad T, Kazim N, Adhikari A, Davie J
Oncotarget. 2018; 9(26):18084-18098.
PMID: 29719592
PMC: 5915059.
DOI: 10.18632/oncotarget.24726.
Chen E, Ricciotti R, Futran N, Oda D
Head Neck Pathol. 2016; 11(3):321-326.
PMID: 27896667
PMC: 5550390.
DOI: 10.1007/s12105-016-0771-0.
Bressner J, McCarthy E, Fayad L, Morris C
Skeletal Radiol. 2016; 45(10):1391-5.
PMID: 27412560
DOI: 10.1007/s00256-016-2430-7.
Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS).
Lacey A, Hedrick E, Li X, Patel K, Doddapaneni R, Singh M
Oncotarget. 2016; 7(21):31257-69.
PMID: 27144436
PMC: 5058754.
DOI: 10.18632/oncotarget.9112.
FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
Kuda M, Kohashi K, Yamada Y, Maekawa A, Kinoshita Y, Nakatsura T
Tumour Biol. 2015; 37(4):5213-23.
PMID: 26553361
DOI: 10.1007/s13277-015-4351-9.
Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Hedrick E, Crose L, Linardic C, Safe S
Mol Cancer Ther. 2015; 14(9):2143-53.
PMID: 26162688
PMC: 4618474.
DOI: 10.1158/1535-7163.MCT-15-0148.
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
Phelps D, Bondra K, Seum S, Chronowski C, Leasure J, Kurmasheva R
Pediatr Blood Cancer. 2015; 62(8):1345-52.
PMID: 25832557
PMC: 4563820.
DOI: 10.1002/pbc.25465.
Rhabdomyoblastic Differentiation in Head and Neck Malignancies Other Than Rhabdomyosarcoma.
Bishop J, Thompson L, Cardesa A, Barnes L, Lewis Jr J, Triantafyllou A
Head Neck Pathol. 2015; 9(4):507-18.
PMID: 25757816
PMC: 4651923.
DOI: 10.1007/s12105-015-0624-2.
GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
Srivastava R, Kaylani S, Edrees N, Li C, Talwelkar S, Xu J
Oncotarget. 2014; 5(23):12151-65.
PMID: 25432075
PMC: 4322980.
DOI: 10.18632/oncotarget.2569.
Early life factors and risk of childhood rhabdomyosarcoma.
Shrestha A, Ritz B, Ognjanovic S, Lombardi C, Wilhelm M, Heck J
Front Public Health. 2013; 1:17.
PMID: 24350186
PMC: 3854857.
DOI: 10.3389/fpubh.2013.00017.
Classification of rhabdomyosarcoma and its molecular basis.
Parham D, Barr F
Adv Anat Pathol. 2013; 20(6):387-97.
PMID: 24113309
PMC: 6637949.
DOI: 10.1097/PAP.0b013e3182a92d0d.
Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn E, Mercado G, Lae M, Ladanyi M
Oncol Rep. 2013; 30(2):968-78.
PMID: 23733015
PMC: 3776721.
DOI: 10.3892/or.2013.2513.
A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.
Olanich M, Barr F
Expert Opin Ther Targets. 2013; 17(5):607-23.
PMID: 23432728
PMC: 6699745.
DOI: 10.1517/14728222.2013.772136.
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Yeung C, Ngo V, Grohar P, Arnaldez F, Asante A, Wan X
Oncogene. 2013; 32(47):5429-38.
PMID: 23318429
PMC: 3898328.
DOI: 10.1038/onc.2012.590.
Rhabdomyosarcomas: an overview on the experimental animal models.
Zanola A, Rossi S, Faggi F, Monti E, Fanzani A
J Cell Mol Med. 2012; 16(7):1377-91.
PMID: 22225829
PMC: 3823208.
DOI: 10.1111/j.1582-4934.2011.01518.x.
Zebrafish models of rhabdomyosarcoma.
Chen E, Langenau D
Methods Cell Biol. 2011; 105:383-402.
PMID: 21951539
PMC: 3615705.
DOI: 10.1016/B978-0-12-381320-6.00016-3.
Caveolins in rhabdomyosarcoma.
Rossi S, Poliani P, Missale C, Monti E, Fanzani A
J Cell Mol Med. 2011; 15(12):2553-68.
PMID: 21707915
PMC: 4373424.
DOI: 10.1111/j.1582-4934.2011.01364.x.
Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S
Mol Cancer Ther. 2009; 8(11):3024-35.
PMID: 19887553
PMC: 2783569.
DOI: 10.1158/1535-7163.MCT-09-0365.